MRNA 10-K Analysis: The 78% Margin Platform Hidden Behind -158% Operating Losses
Moderna reported a -158% operating margin on $1.9 billion in FY2025 revenue. But the 10-K reveals something the earnings release doesn't: Moderna's mRNA manufacturing platform produces vaccines at a 78.2% core gross margin — 23 percentage points higher than reported. The gap? $472 million in transitional costs that have declined 87% since 2023. With $8.1 billion in total financial assets providing 4.3 years of runway, and two date-certain catalysts (Europe lockout expiry Dec 2026, FDA flu vaccine decision Aug 5, 2026) approaching, the central question shifts from survival to revenue inflection timing.